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Summary
Objective: The aim of this study was to investigate the effects of different growth factors on the chondrogenic potential of human bone marrow
stromal cells (BMSC).
Design: Different growth factors which have been shown to sustain the osteogenic potential of BMSC during their ‘in vitro’ expansion were
assayed for the maintenance of the chondrogenic potential. We compared the ability of BMSC to reconstitute cartilage in vitro with their ability
to form bone on hydroxyapatite microporous particles in an ectopic bone formation assay.
Results: Among the factors assayed, fibroblast growth factor 2 (FGF2) was the most effective in promoting growth of BMSC ‘in vitro’. For all
growth factors tested, we have found a complete overlap of the enhancement of chondrogenic and osteogenic potential. Any factor, either
promoting or depressing bone formation, exerted the same effect on the chondrogenic potential of human BMSC. In particular, FGF2, either
alone or in combination with other factors, strongly supported the formation of bone as well as of cartilage.
Conclusions: We conclude that FGF2 maintains human BMSC in an immature state allowing their ‘in vitro’ expansion. Expanded cells retain
the chondro- osteogenic potential. Interestingly, the chondrogenic potential of BMSC ‘in vitro’ is directly related to their ability to form bone
‘in vivo’. BMSC expanded ‘ex vivo’ are presently being proposed for cell therapy of bone defects. ‘In vitro’ chondrogenesis may be regarded
as a rapid prediction assay to assess cell ability to form bone after ‘in vivo’ transplant. © 2001 OsteoArthritis Research Society International
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Endochondral bone formation occurs through a complex
series of events involving the proliferation and conden-
sation of mesenchymal precursors committed to prechon-
drogenic cells which will eventually produce a template of
hypertrophic cartilage. Stage specific modifications in the
morphology and the biochemistry of mesenchymal cells
and in the structure and composition of the extracellular
matrix deposited characterize this process. The progres-
sion from undifferentiated stem cells to hypertrophic
chondrocytes and to osteoblasts requires both intrinsic (the
genomic potential of the cells) and extrinsic (the local
microenvironment) factors created by the extracellular
matrix, systemic factors and other signalling molecules
(hormones, growth factors and cytokines) that can
modulate the cellular metabolism in an autocrine/paracrine
manner1. Stromal cells isolated from mammal postnatal
bone marrow have been extensively demonstrated to have
the potential to differentiate into specialized connective
tissue cells and to give rise to skeletal tissues2–8. In vitro
bone marrow stromal cells (BMSC) form colonies of fibro-
blastlike cells which can be expanded and assayed for their
osteogenic and chondrogenic potential either in vitro or in
vivo by means of defined assays5–7,9. The in vitro ability ofS36human and rabbit BMSC to differentiate into chondrocytes
and to form cartilage has been clearly shown5. The effects
of several growth factors on the proliferation and activity of
bone cells and marrow stromal cells have been investi-
gated by several groups7,10–18. The increase of BMSC
proliferation rate and osteogenic potential by growth
factors has been also demonstrated7,14.
Few attempts have been made instead to establish
the influence of growth factors and hormones on the
chondrogenic potential of these cells.
The present study was thus designed to investigate the
effects of different growth factors on the chondrogenic
potential of human BMSC.Materials and methodsAddress correspondence to: Rodolfo Quarto MD, Laboratorio di
Differenziamento Cellulare, Centro di Biotecnologie Avanzate/
Istituto Nazionale per la Ricerca sul Cancro, Largo R. Benzi n. 10,
16132 Genova, Italy. Tel: +39-010-5737 240.
Fax: +39-010-5737 405; E-mail: quarto@ermes.cba.unige.itBMSC CULTURE
Informed consent was obtained from all individuals
involved in this study as approved by the competent
institutional ethical committee. Bone marrow (BM) samples
from the posterior iliac crest were collected from normal
donors under general anaesthesia during the surgical
harvest procedure for bone marrow transplant (BMT).
Bone marrow samples were washed twice with
phosphate buffered saline (PBS) and the nucleated cells
were counted with a nuclear stain (0.1% methyl violet in
0.1 M citric acid), suspended in Coon’s modified Ham’s
F12 medium supplemented with 10% fetal calf serum
(FCS) (Kallergen), 100 IU/ml penicillin and 100 g/ml
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added (when indicated) at the beginning of each culture. All
the growth factors used were human recombinant (Austral
Biologicals). The medium was changed 2 days after the
original plating and then twice a week. When the cultures
became nearly confluent, cells were detached with 0.05%
trypsin-0.01% EDTA (Sigma) and either replated for further
expansion or used for tissue reconstitution experiments.COLONY FORMING EFFICIENCY
To evaluate colony forming efficiency (expressed as ratio
between the number of colonies obtained and the number
of cells plated), 5×105 nucleated bone marrow cells were
plated in 60 mm dishes (approx 1.8×104 cells/cm2). The
medium was changed after 4 days and then twice a week.
After 2 weeks cells were washed with PBS pH 7.2, fixed
with formaline 4% in PBS, stained with 1% methylene blue
in borate buffer (10 mM, pH 8.8) for 30 minutes and then
washed with distilled water. Images of the dishes were
acquired by a Cohu b/w camera, digitized by LG-3 frame
grabber card (Scion Corporation, Frederick, MD) into a
Quadra 840AV Macintosh computer and analysed by the
NIH-Image public domain software. On this platform a
particular computer programme (macro) was integrated to
automatically process each dish image: colonies were
counted, their total area was calculated and the average
number and size of colonies formed in different culture
conditions was derived.IN VITRO CARTILAGE RECONSTITUTION: PELLET CULTURE
Cartilage formation was obtained ‘in vitro’ according to
the procedures described by Johnstone and coworkers
with minor modification5.
At day 0, primary or first passage BMSC were detached
from culture dishes, counted and 2.5×105 cells were
centrifuged in 15 ml polypropylene conical tubes. The
pelletted cells were maintained for 24 h of incubation with
10% FCS. In this time period the cells formed a spherical
aggregate at the bottom of the tube. Culture medium was
then replaced with serum free Coon’s modified Ham’s F12
medium supplemented with 6.25 g/ml bovine insulin,
6.25 g/ml human apo-transferrin, 5.35 g/ml bovine
serum albumin, 1.25 g/ml linoleic acid, 1 mM sodium
pyruvate (basal medium). Human recombinant transform-
ing growth factor 1 (TGF1) (10 ng/ml), dexamethasone
(10−7 M) and ascorbic acid (50 g/ml) were supplemented
to the basal medium as differentiating factors. These
factors were added every other day and the medium was
changed twice a week. Pellet cultures were incubated at
37°C and harvested at day 15. Samples were formalin
fixed, paraffin embedded, sectioned, stained with toluidine
blue and analysed for cartilage formation using a Zeiss
Axiophot microscope.
Cartilage formation was considered negative when
either sporadic or no lacunae were detected, whereas it
was scored as positive in the presence of a clearly detect-
able cartilagineous metachromatic matrix with chondro-
cytes embedded in lacunae in at least three histological
sections from duplicate samples.ECTOPIC BONE FORMATION ASSAY
First passage BMSC (about 16 cell doublings) were
detached from the dishes with 0.05% trypsin and 0.01%EDTA, washed in PBS and resuspended at 2.5×105 cells/
100 l of 40 mg/ml fibrinogen (Immuno) solution in PBS;
100 l of fibrinogen cell suspension were combined with
10 mg of 100% hydroxyapatite particles (average particle
size 125 m), 25 NIH units of thrombin (Baldacci) were
added and the reaction allowed to proceed at 37°C
for 10 min. Ceramic particles/BMSC composites were
subcutaneously implanted in recipient mice just after
loading.
Recipient immunodepressed (ID) mice (CD-1 nu/nu)
1 month old were purchased from Charles River Italia, kept
in a controlled environment and given free access to food
and water. Mice were treated according to institutional
guidelines. Animals were anaesthetized by intramuscular
injection of xilazine (20 g/ml) and ketamine (30 g/ml).
Grafts were implanted subcutaneously on the back of the
mice (up to six implants for each animal). Animals were
sacrificed 8 weeks after implantation. Grafts were removed
and processed for histological analysis. Samples were
decalcified (Osteodec, Bio-Optica) according to manufac-
turer instructions, paraffin embedded, sectioned, stained
with haematoxylin/eosin and analysed for bone tissue
using a Zeiss Axiophot microscope.
Bone formation was considered negative when little or
no bone trabeculae were detected in at least three histo-
logical sections from duplicate samples, whereas it was
scored as positive when the presence of bone matrix was
observed in at least two-thirds of the surface of each
section analysed from duplicate samples.ResultsTable I
Number and size of BMSC colonies obtained in the presence of
different factors
Condition Colony
average size
(±SD)
Colony
average no.
(±SD)
Ctrl 2.6±0.45 40.0±3.7
FGF2 4.6±0.42 26.6±4.4
PDGFbb 2.8±0.72 28.5±5.2
PDGFbb+FGF2 5.2±0.20 27.0±5.9
EGF 2.9±0.51 35.0±2.1
EGF+FGF2 4.5±0.73 25.0±2.4
IGF-I 2.4±0.47 53.5±0.7
IGF-I+FGF2 4.5±0.95 38.5±2.1
A defined number of nucleated marrow cells was plated in the
presence of different growth factors. After 15 days of culture,
dishes were washed, fixed, stained and analysed as described in
the Methods section. Colony size is expressed in mm±SD. Colony
number is expressed as the number of actual colonies±SD
obtained after plating 5×105 bone marrow nucleated cells. Ctrl=
fetal calf serum 10% without any other growth factor supplement.EFFECT OF DIFFERENT GROWTH FACTORS ON BMSC COLONY
FORMATION
Human bone marrow nucleated cells were plated in a
medium containing 10% FCS. In some dishes different
growth factors were added at the indicated concentration to
study their effect on colony formation. In particular, based
on previous experimental work where growth factors were
assayed in terms of sustaining BMSC osteogenic potential
during their ‘in vitro’ expansion7 the following factors were
tested: Epidermal growth factor (EGF) (1 ng/ml), platelet
S38 M. Mastrogiacomo et al.: Chondrogenic potential of human BMSCFig. 1. Cartilage and bone formation by BMSC. The ‘in vivo’ osteogenic potential (Panels A,C,E,G) of BMSC expanded with the growth
factors tested was compared with their ‘in vitro’ chondrogenic potential (Panels B,D,F,H). Bone and cartilage formation was evident in all the
samples prepared with BMSC stimulated with FGF2 (A and B). When IGF-I alone was used in BMSC expansion, it yielded a poor bone and
cartilage formation, if any (C, D). When FGF2 was added together with IGF-I, it restored both bone and cartilage forming ability of BMSC (E,
F). When expanded in medium containing FCS with no other growth factor supplement, BMSC yielded a poor, basically negative both bone
and cartilage formation (G, H). bm=bone matrix; ad=adipose tissue; ft=fibrous tissue; c=cartilage. Bar=100 m.
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growth factor 2 (FGF2) (1 ng/ml), insulin-like growth factor I
(IGF-I)(1 ng/ml). All factors were assayed either alone or in
combination with FGF2. The factor concentration indicated
refers to the actual amount added and does not consider
factors or binding proteins present in the fetal calf serum.
Average size of colonies was strongly increased by the
addition of FGF2 (1.8 fold at 1 ng/ml) (Table I). When used
alone, the other factors did not influence significantly
BMSC colony size (Table I). All the cultures stimulated with
the various growth factors combined with FGF2 displayed
an increased colony size comparable with the increase
obtained when FGF2 alone was used.OSTEOGENIC AND CHONDROGENIC POTENTIAL OF BMSC
The ‘in vivo’ osteogenic potential of BMSC expanded
in the presence of the growth factors was studied and
compared with their ‘in vitro’ chondrogenic potential.
Cultures of cells expanded either with or without factor
supplement were split into two equivalent aliquots. One
aliquot was implanted ‘in vivo’ for an ectopic bone formation
assay as described in the methods section. After 8 weeks
samples were harvested and processed for histology. The
other half of the culture was tested for cartilage formation
in vitro. After 2 weeks samples were formalin-fixed and
processed for histology.
Bone formation was evident in all the samples loaded
with BMSC stimulated with FGF2, either with or without the
addition of other factors (Fig. 1A, G; Table II). All other
factors used in BMSC expansion yielded a poor, barely
detectable bone formation (Fig. 1E, Table II).
As revealed by the ‘in vitro’ pellet culture, cartilage
formation paralleled the results of the ‘in vivo’ bone for-
mation. FGF2 supplement was critical also for the mainten-
ance of the chondrogenic potential. In fact, cartilage was
clearly formed in all the cultures which had been previously
treated with FGF2 both alone and in combination with other
factors (Fig. 1B, H, Table II). Instead, cartilage was poorly
formed or not formed at all in cultures treated with other
factors alone (Fig. 1F, Table II).
BMSC expanded in FCS without any growth factor
supplement essentially failed to yield both bone and
cartilage formation (Fig. 1C, D, Table II).Discussion
Bone marrow derived stromal cells are able to differ-
entiate into specialized connective tissue cells and to give
rise to skeletal tissues2–8 and their differentiation potential
can be assayed either in vitro or in vivo by means of
defined assays5–7,9. The in vitro ability of mammalian
BMSC to differentiate into chondrocytes and to form carti-
lage has been clearly shown5. Several growth factors are
effective on proliferation and activity of bone and marrow
stromal cells7,10–18. Furthermore, BMSC proliferation rate
and osteogenic potential can be modulated by particular
factors7,14. From the literature, it is not clear yet whether
growth factors influence also the chondrogenic potential of
these cells. We therefore wanted to verify whether factors
effective on BMSC as to osteogenic potential would exert
the same effect as to chondrogenic potential.
It is known that FGF2 is a potent modulator of prolifer-
ation and activity of bone cells18 and marrow stromal
cells7,10–17, although it might not always act directly10. The
addition of FGF2 to the BMSC culture medium in the
presence of serum yields a reproducible and constant level
of cell proliferation and ‘in vivo’ bone reconstitution7,14.
None of the other factors we have tested in this study had
a comparable effect on BMSC as to both size and number
of marrow fibroblast colonies obtained. On the other hand,
FGF2 had a dominant effect when added in combination
with any of the other factors tested and no cooperative
effect was detected in these combinations. In fact, the size
of BMSC colonies was larger whenever FGF2 was present
in the medium despite the addition of any of the other factor
tested. Even in the bone formation experiments the FGF2
dominant effect was evident. When in fact the cells
expanded in the presence of growth factors either with or
without FGF2 were implanted in vivo in ID mice, only cells
expanded in any of the conditions where FGF2 had been
added did form bone. Again no cooperative effect among
different factors was detected.
Interestingly, as revealed by the ‘in vitro’ assay, the
results of cartilage formation experiments, strictly paral-
leled the results of the ‘in vivo’ bone formation assays. In
fact, when tested ‘in vitro’, cells yielding a good bone
formation were very effective in cartilage formation,
whereas cells yielding a poor bone formation were poor in
cartilage formation as well.
Implants of porous bioceramic loaded with BMSC are
being proposed to repair large bone defects19,20. Since
‘in vitro’ cartilage formation closely parallels ‘in vivo’ bone
formation, we suggest the ‘pellet assay’ for cartilage for-
mation to be a predictive assay of the osteogenic potential
of ‘ex vivo’ expanded human BMSC. This assay could
make easier to quality test preparations of human BMSC
and could by far be a less expensive and less time
consuming alternative to the traditional ‘in vivo’ bone
formation assay.
In conclusion, FGF2 maintains human BMSC in an
immature state allowing their ‘in vitro’ expansion and their
maintenance as chondro-osteo-progenitor cells.Acknowledgments
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(ESA).Table II
Effect of different growth factors on cartilage and bone formation
by BMSC
Condition Cartilage
formation
‘in vitro’
Bone
formation
‘in vivo’
Ctrl − −
FGF2 + +
PDGFbb − −
PDGFbb+FGF2 + +
EGF − −
EGF+FGF2 + +
IGF-I − −
IGF-I+FGF2 + +
Duplicate cultures of human BMSC stimulated with various
growth factors were assayed for their ability to reconstitute carti-
lage and bone as described in the Methods section. Ctrl= fetal calf
serum 10% without any other growth factor supplement.
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